Efficacy of a Multistep Strategy for Helicobacter Pylori Eradication
Overview
Pharmacology
Authors
Affiliations
Background: Helicobacter pylori eradication therapies do not achieve 100% success rates. Antibiotic resistant strains are among the major causes of failure. Current recommendations concerning the management of treatment failures are not fully clear.
Aim: To evaluate the efficacy of a multi-step therapeutic strategy in a large group of infected patients.
Methods: A total of 2606 H. pylori-positive patients were administered tinidazole, clarithromycin and a proton pump inhibitor for 1 week. Patients with continuing infection were then given a second 1-week course of amoxycillin, clarithromycin and ranitidine bismuth citrate. Patients still infected after the second course underwent upper gastrointestinal endoscopy with H. pylori culture, and then received a 1-week quadruple proton pump inhibitor-bismuth based scheme established on H. pylori antibiotic sensitivity.
Results: After the first step, eradication was achieved in 2063 out of 2413 patients [86% per protocol analysis (PP); 79% intention-to-treat analysis (ITT)]. First-step failures (350 out of 2413; 14.5% PP) showed second-step eradication rates of 82% (271 out of 329 patients, PP; 77% ITT). The specific quadruple therapy for second-step failures (58 out of 329, 18% PP) achieved 77% (30 out of 39 patients, PP) or 52% (ITT) success. This algorithm led to overall eradication rates of 99% (PP) or 91% (ITT).
Conclusions: This multi-step strategy succeeded in a high percentage of H. pylori infected patients. Given the lack of precise guidelines on treatment failures, assessing H. pylori sensitivity to antibiotics only after failure of the second treatment could be suggested in clinical practice.
Treatment of infection and gastric ulcer: Need for novel Pharmaceutical formulation.
Gupta A, Shetty S, Mutalik S, Chandrashekar H R, K N, Mathew E Heliyon. 2023; 9(10):e20406.
PMID: 37810864 PMC: 10550623. DOI: 10.1016/j.heliyon.2023.e20406.
Empirical vs. Susceptibility-Guided Treatment of Infection: A Systematic Review and Meta-Analysis.
Nyssen O, Espada M, Gisbert J Front Microbiol. 2022; 13:913436.
PMID: 35774456 PMC: 9237546. DOI: 10.3389/fmicb.2022.913436.
Treatment Approach of Refractory : A Comprehensive Review.
Cortes P, Nelson A, Bi Y, Stancampiano F, Murray L, Pujalte G J Prim Care Community Health. 2021; 12:21501327211014087.
PMID: 33949229 PMC: 8114244. DOI: 10.1177/21501327211014087.
Treatment of Refractory Infection-Tailored or Empirical Therapy.
Liou J, Lee Y, Wu M Gut Liver. 2021; 16(1):8-18.
PMID: 33782215 PMC: 8761919. DOI: 10.5009/gnl20330.
Rifabutin for the Treatment of Infection: A Review.
Gisbert J Pathogens. 2020; 10(1).
PMID: 33379336 PMC: 7823349. DOI: 10.3390/pathogens10010015.